TY - JOUR
T1 - American Registry of Pathology Expert Opinions
T2 - Immunohistochemical evaluation of classic Hodgkin lymphoma
AU - O'Malley, Dennis P.
AU - Dogan, Ahmet
AU - Fedoriw, Yuri
AU - Medeiros, L. Jeffrey
AU - Ok, Chi Young
AU - Salama, Mohamed E.
N1 - Funding Information:
This study was funded by an unrestricted education grant by NeoGenomics Laboratories .
Publisher Copyright:
© 2019 The Authors
PY - 2019/4
Y1 - 2019/4
N2 - The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested additional markers include: P63, CD23, CD45 and CD79a. When considering a differential diagnosis that includes anaplastic large cell lymphoma we suggest: ALK, CD45, pan T cell antigens (such as CD2, CD5, CD7, and CD43), and cytotoxic markers (granzyme, perforin, and TIA1). If peripheral T cell lymphoma or T cell lymphomas of follicular helper origin are considered in the differential diagnosis, the following panel is recommended: pan T cell antigens, CD4, CD8, one or more follicular dendritic cell markers, and assessment for Epstein-Barr virus (EBV) infection, preferably EBV encoded RNA (EBER) as assessed by in situ hybridization When the differential diagnosis includes nodular lymphocyte predominant Hodgkin lymphoma, recommended additional studies include OCT2, CD21 and/or CD23, PD1, and assessment for EBV infection. The authors recognize that these panels may not be adequate to completely characterize other lymphomas, but these panels will usually be sufficient to distinguish classic Hodgkin lymphoma from other lymphoma types.
AB - The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested additional markers include: P63, CD23, CD45 and CD79a. When considering a differential diagnosis that includes anaplastic large cell lymphoma we suggest: ALK, CD45, pan T cell antigens (such as CD2, CD5, CD7, and CD43), and cytotoxic markers (granzyme, perforin, and TIA1). If peripheral T cell lymphoma or T cell lymphomas of follicular helper origin are considered in the differential diagnosis, the following panel is recommended: pan T cell antigens, CD4, CD8, one or more follicular dendritic cell markers, and assessment for Epstein-Barr virus (EBV) infection, preferably EBV encoded RNA (EBER) as assessed by in situ hybridization When the differential diagnosis includes nodular lymphocyte predominant Hodgkin lymphoma, recommended additional studies include OCT2, CD21 and/or CD23, PD1, and assessment for EBV infection. The authors recognize that these panels may not be adequate to completely characterize other lymphomas, but these panels will usually be sufficient to distinguish classic Hodgkin lymphoma from other lymphoma types.
KW - Anaplastic large cell lymphoma
KW - Angioimmunoblastic T cell lymphoma
KW - CD15
KW - CD30
KW - Classic Hodgkin lymphoma
KW - Differential diagnosis
KW - Diffuse large B cell lymphoma
KW - Gray zone lymphoma
KW - Immunohistochemistry
KW - Nodular lymphocyte predominant Hodgkin lymphoma
KW - PAX5
KW - Peripheral T cell lymphoma
KW - Primary mediastinal large B cell lymphoma
KW - T cell/histiocyte rich large B cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85061785418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061785418&partnerID=8YFLogxK
U2 - 10.1016/j.anndiagpath.2019.02.001
DO - 10.1016/j.anndiagpath.2019.02.001
M3 - Article
C2 - 30802809
AN - SCOPUS:85061785418
SN - 1092-9134
VL - 39
SP - 105
EP - 110
JO - Annals of Diagnostic Pathology
JF - Annals of Diagnostic Pathology
ER -